Peridot Acquisition Corp. Class A PDAC 深 沪
已收盘 08-10 16:00:00 美东时间
11.23
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 11.23
- 总市值 4.21亿
- 52周最高 125.92
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 70.48
- 委 比 0.00%
- 总股本 3750.00万
- 历史最高 125.92
- 量 比 0
- 振 幅 0.00%
- 历史最低 70.48
- 每 手 1
- 风险率 0.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多超800亿，刷新纪录！中国医药出海史上最大一单来了
812.2亿——中国创新药出海交易的金额纪录，又被刷新了。 这笔交易总金额预计高达114亿美元，约合人民币 812.2 亿元，仅首付款就高达12亿美元，约合人民...
10-25 16:20
Verastem Reveals Preliminary Data From The First Two Dose Levels In Its Ongoing Phase 1/2a Clinical Trial Evaluating VS-7375; First Two Monotherapy Dose Levels Cleared, With No Dose-limiting Toxicities Reported; Enrollment Initiated For VS-7375 In Combination With Cetuximab In Patients With Advanced KRAS G12D Mutant Solid Tumors, Including Colorectal Cancer
First two monotherapy dose levels (400 mg QD and 600 mg QD) cleared, with no dose-limiting toxicities reportedPromising anti-tumor activity observed in patients with various solid tumors, including advanced pancreatic
10-24 04:08
劲方医药(02595.HK)GFH375联合西妥昔单抗或化疗方案的Ib/II期研究完成首例患者给药
【财华社讯】劲方医药(02595.HK)公布，GFH375联合疗法治疗KRAS G12D突变型晚期实体瘤的Ib/II期研究首例患者在北京大学肿瘤医院完成入组。此...
10-22 08:56
劲方医药-B(02595)：KRAS G12D抑制剂GFH375治疗晚期胰腺导管腺癌研究数据呈列于2025年ESMO年会口头报告及突破性研究摘要
劲方医药-B(02595)发布公告，GFH375单药治疗KRAS G12D突变型胰腺导管腺癌 (PDAC)患者数据于德国当地时间10月19日登陆2025年欧洲肿...
10-20 08:54
Cellectar Biosciences Presented Preclinical Data On CLR 121225, A Novel Actinium-Based Alpha-Emitter For Pancreatic Ductal Adenocarcinoma Which Has Completed IND-Enabling Studies And May Advance To A Phase 1 Trial
Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief
10-14 20:37
Elicio Therapeutics Announces Planned Initiation Of Investigator-Initiated Phase 1 Trial Of ELI-002 7P In Combination With Chemotherapy And Anti-PD1 Checkpoint Inhibitor In Borderline And Resectable PDAC
Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor ("CPI") in the neoadjuvant setting Trial is anticipated to begin enrolling in H1'2026 BOSTON, Sept. 29, 2025 (GLOBE
09-29 20:19
劲方医药正式登陆港交所：开盘上涨超136%，多项发行数据刷新港股18A纪录
港股IPO阶段首个同时手握上市新药与多个BD授权收入的Biotech。 作者｜Stone Jin、罗宾 据IPO早知道消息，劲方医药科技（上海）股份有限...
09-19 11:32
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August...
09-17 00:29
